{"analyses":[{"ciLowerLimit":".72","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.23","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":".94"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20.1","upperLimit":"26.3","value":"23.2"},{"groupId":"OG001","lowerLimit":"19.8","upperLimit":"26.0","value":"24"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"346"},{"groupId":"OG001","value":"346"}],"units":"Participants"}],"description":"First Quartile Overall Survival","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses.\n\nBevacizumab: Given IV\n\nCarboplatin: Given IV\n\nComputed Tomography: Correlative studies\n\nPaclitaxel: Given IV","id":"OG000","title":"Arm I (Adjuvant Chemotherapy Suboptimally Debulked)"},{"description":"Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15 and carboplatin IV over 30 minutes on day 1. Treatment repeats every 21 days for 6 courses. Patients undergo interval cytoreductive surgery between courses 3 and 4.\n\nBevacizumab: Given IV\n\nCarboplatin: Given IV\n\nComputed Tomography: Correlative studies\n\nPaclitaxel: Given IV\n\nTherapeutic Conventional Surgery: Undergo surgery","id":"OG001","title":"Arm II (Neoadjuvant Chemotherapy)"}],"paramType":"MEDIAN","populationDescription":"Whole sample","reportingStatus":"POSTED","timeFrame":"The timeframe is from enrollment onto the study up to 3 years after enrollment","title":"Median Duration of First Quartile Survival","type":"SECONDARY","unitOfMeasure":"months"}